surmount trials tirzepatide SURMOUNT-1 (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants ESC 2025: post-hoc SURMOUNT-5 data
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12

01200-X/asset/1ec2c191-5a64-4856-842f-bfa65a8fabc6/main.assets/gr2.jpg)

























